<?xml version="1.0" encoding="UTF-8"?>
<p>Another antiviral drug assayed toward SARS-CoV-2 is Umifenovir, a licensed antiviral exploited for the prophylaxis and treatment of influenza viruses (Arbidol), which demonstrated good pharmacokinetics when absorbed by the organism (
 <xref rid="B169" ref-type="bibr">Proskurnina et al., 2020</xref>). This drug has an antiviral effect against SARS-CoV 
 <italic>in vitro</italic> at 50 μg mL
 <sup>–1</sup> (
 <xref rid="B113" ref-type="bibr">Khamitov et al., 2008</xref>). Lian and coworkers coordinated an observational study with 81 patients with moderate to severe SARS-CoV-2 infection (
 <xref rid="B133" ref-type="bibr">Lian et al., 2020</xref>) that demonstrated that Umifenovir neither shortened the hospitalization period nor improved prognosis in infected patients (
 <xref rid="B133" ref-type="bibr">Lian et al., 2020</xref>).
</p>
